mRNA-1647 Vaccine
Showing 26 - 50 of 8,830
SARS-CoV-2 Trial (SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 variant mRNA vaccine low dose
- SARS-CoV-2 variant mRNA vaccine high dose
- (no location specified)
Oct 30, 2022
Liver Cancer, Hepatocellular Carcinoma Trial in Chengdu (HBV mRNA vaccine)
Recruiting
- Liver Cancer
- Hepatocellular Carcinoma
- HBV mRNA vaccine
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Feb 12, 2023
Malignant Tumors Trial in Chengdu (EBV mRNA vaccine)
Recruiting
- Malignant Tumors
- EBV mRNA vaccine
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Jan 27, 2023
Influenza Immunization Trial in Australia (H3 mRNA / LNP Vaccine, Quadrivalent recombinant influenza Vaccine (RIV4))
Recruiting
- Influenza Immunization
- H3 mRNA / LNP Vaccine
- Quadrivalent recombinant influenza Vaccine (RIV4)
-
Herston, Queensland, Australia
- +3 more
May 1, 2023
COVID-19 Trial in Kunming (RQ3013, RQ3025, RQ3027)
Recruiting
- COVID-19
- RQ3013
- +2 more
-
Kunming, Yunnan, ChinaThe Affiliated Hospital of Yunnan University
Jun 22, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
- Saline solution
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Feb 26, 2023
SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)
Active, not recruiting
- SARS-CoV-2
- RBMRNA-176
- Placebo
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023
SARS-CoV-2 Trial (SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
- +2 more
- (no location specified)
Dec 1, 2022
Influenza Trial in United States (mRNA-1010, mRNA-1010.4, mRNA-1010.6)
Recruiting
- Influenza
- mRNA-1010
- +2 more
-
Hollywood, Florida
- +9 more
May 11, 2023
SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
Seasonal Influenza Trial in United States (mRNA-1030, mRNA-1020, mRNA-1010)
Completed
- Seasonal Influenza
- mRNA-1030
- +3 more
-
Phoenix, Arizona
- +14 more
Dec 5, 2022
Influenza, COVID-19, Influenza Immunogencity Trial in United States (Simultaneous Vaccination (Influenza Vaccine and mRNA COVID
Not yet recruiting
- Influenza
- +3 more
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
- +2 more
-
Phoenix, Arizona
- +7 more
Aug 30, 2023
Influenza Trial in Durham (Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP
Not yet recruiting
- Influenza
- Influenza Virus Quadrivalent Inactivated Vaccine
- +2 more
-
Durham, North CarolinaDuke Human Vaccine Institute - Duke Vaccine and Trials Unit
Feb 23, 2023
HIV-1-infection Trial in Kigali, Johannesburg (eOD-GT8 60mer mRNA Vaccine (100µg))
Active, not recruiting
- HIV-1-infection
- eOD-GT8 60mer mRNA Vaccine (100µg)
-
Kigali, Rwanda
- +1 more
Sep 9, 2022
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01 in combination with standard adjuvant therapy)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01 in combination with standard adjuvant therapy
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
COVID-19, COVID-19 Immunisation Trial in Decatur, Bethesda, Seattle (mRNA-1273)
Completed
- COVID-19
- COVID-19 Immunisation
- mRNA-1273
-
Decatur, Georgia
- +2 more
Jan 26, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Glioblastoma Trial in Belgium, Germany, Netherlands (CV09050101 mRNA vaccine (CVGBM) 12 µg, CV09050101 mRNA vaccine (CVGBM) 25
Recruiting
- Glioblastoma
- CV09050101 mRNA vaccine (CVGBM) 12 μg
- +5 more
-
Woluwe-Saint-Lambert, Brussels, Belgium
- +14 more
Jul 12, 2023
SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
- 0.9% sodium chloride solution
-
Islamabad, PakistanSindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023
Influenza, Human Trial (Flu mRNA, Control 1, Control 2)
Not yet recruiting
- Influenza, Human
- Flu mRNA
- +2 more
- (no location specified)
Apr 21, 2023
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection Trial (Novavax COVID-19 vaccine (2023-2024 formula XBB containing),
Not yet recruiting
- COVID-19
- +4 more
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing)
- Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- (no location specified)
Sep 29, 2023
Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)
Not yet recruiting
- Immunogenicity
- Safety
- Phase II:SWIM816;SARS-Cov-2;
- +3 more
- (no location specified)
Jun 18, 2023
SARS-CoV2 Infection, Coronavirus Infection Trial in Hamilton (mRNA- COVID-19, Prevnar13)
Not yet recruiting
- SARS-CoV2 Infection
- Coronavirus Infection
- mRNA- COVID-19
- Prevnar13
-
Hamilton, Ontario, CanadaMcMaster University
Jun 29, 2022
Healthy, Chronic Stable Illness Trial in United States (casirivimab+imdevimab, Moderna mRNA-1273 vaccine)
Completed
- Healthy
- Chronic Stable Illness
- casirivimab+imdevimab
- Moderna mRNA-1273 vaccine
-
Little Rock, Arkansas
- +5 more
Jan 9, 2023